What amount sold does ELIXIRGEN THERAPEUTICS, INC. report in Form D filings?

The latest linked filings report $28.4M sold across 7 identified offering(s). 1 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was ELIXIRGEN THERAPEUTICS, INC.'s most recent SEC filing?

ELIXIRGEN THERAPEUTICS, INC.'s most recent Form D filing was on 2025-11-13.

How many investors does ELIXIRGEN THERAPEUTICS, INC. have?

The most recent Form D filing lists 1 investor(s).

What type of securities does ELIXIRGEN THERAPEUTICS, INC. offer?

ELIXIRGEN THERAPEUTICS, INC.'s SEC Form D filings indicate debt offerings.

ELIXIRGEN THERAPEUTICS, INC.

CIK: 0001744333·Biotechnology·BALTIMORE, MD·Corporation

Reported Sold

$28,399,971

Total Filings

Identified Offerings

Last Filed

Nov 13, 2025

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately. 1 unlinked amendment excluded.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Nov 13, 2025Form D — New notice

Reported sold: $4,000,000 · Target: $4,000,000

Rule 506(b)·1 investor

Apr 9, 2025Form D — New notice

Reported sold: $3,600,000 · Target: $3,600,000

Rule 506(b)·2 investors

Feb 12, 2025Form D — New notice

Reported sold: $600,000 · Target: $600,000

Rule 506(b)·2 investors

Dec 1, 2023Form D — New notice

Reported sold: $6,999,988 · Target: $6,999,988

Rule 506(b)·1 investor

Sep 29, 2022Form D — New notice

Reported sold: $5,000,000 · Target: $5,000,000

Rule 506(b)·1 investor

Feb 18, 2021Form D — New notice

Reported sold: $4,199,985 · Target: $5,499,971

Rule 506(b)·2 investors

Aug 17, 2020Form D/A — Amendment

Reported sold: $5,706,889 · Target: $5,706,889

No verified predecessor available.

Rule 506(b)·3 investors

Jun 25, 2018Form D — New notice

Reported sold: $3,999,998 · Target: $3,999,998

Rule 506(b)·1 investor

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

13%

Latest reported sold across 7 identified offerings

$28,399,971

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

1 unlinked amendment excluded.

Key People

AKIHIRO KO

Related Person

Appears on 7 filings

HIROAKI KOBAYASHI

Related Person

Appears on 6 filings

MINORU KO

Related Person

Appears on 6 filings

SHAUNA CALLAHAN

Related Person

Appears on 6 filings

THOMAS WHITE

Related Person

Appears on 5 filings

JEFFREY CLELAND

Related Person

Appears on 4 filings

MINORU S.H. KO

Related Person

Appears on 2 filings

Naonori Kurokawa

Related Person

Appears on 2 filings

Filing History

Date	Type	Offering target	Reported sold	Investors
Nov 13, 2025	New	$4,000,000	$4,000,000	1
Apr 9, 2025	New	$3,600,000	$3,600,000	2
Feb 12, 2025	New	$600,000	$600,000	2
Dec 1, 2023	New	$6,999,988	$6,999,988	1
Sep 29, 2022	New	$5,000,000	$5,000,000	1
Feb 18, 2021	New	$5,499,971	$4,199,985	2
Aug 17, 2020	Amendment	$5,706,889	$5,706,889	3
Jun 25, 2018	New	$3,999,998	$3,999,998	1

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Accufy Diagnostics, Inc.

Biotechnology

Offering target: $2,000,000

Filed Oct 28, 2026